Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of 204 patients with diffuse large B-cell lymphoma (DLBCL) according to the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells and tumor microenvironment

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Characteristic PD-L1 expression in tumor cells [cases (%)] P value PD-L1 expression in tumor microenvironment [cases (%)] P value
Negative Positive Negative Positive
Total 104 100   160 44  
Gender    0.22    0.34
 Male 63 (60.6) 52 (52.0)   93 (58.1) 22 (50.0)  
 Female 41 (39.4) 48 (48.0)   67 (41.9) 22 (50.0)  
Age (years)    0.78    0.92
 ≤ 60 73 (70.2) 72 (72.0)   114 (71.2) 31 (70.5)  
 > 60 31 (29.8) 28 (28.0)   46 (28.8) 13 (29.5)  
Clinical stage    0.04    0.12
 I–II 58 (55.8) 42 (42.0)   83 (51.9) 17 (38.6)  
 III–IV 46 (44.2) 58 (58.0)   77 (48.1) 27 (61.4)  
B symptoms    0.74    0.22
 No 75 (72.1) 70 (70.0)   117 (73.1) 28 (63.6)  
 Yes 29 (27.9) 30 (30.0)   43 (26.9) 16 (36.4)  
Spleen involvement    0.19    0.22
 No 92 (88.5) 82 (82.0)   139 (86.9) 35 (79.5)  
 Yes 12 (11.5) 18 (18.0)   21 (13.1) 9 (20.5)  
IPI    0.09    0.18
 < 3 86 (82.7) 73 (73.0)   128 (80.0) 31 (70.5)  
 ≥ 3 18 (17.3) 27 (27.0)   32 (20.0) 13 (29.5)  
Extranodal involvement    0.67    0.88
 No 42 (40.4) 44 (44.0)   67 (41.9) 19 (43.2)  
 Yes 62 (59.6) 56 (56.0)   93 (58.1) 25 (56.8)  
Bulky diseasea    0.91    0.82
 No 56 (70.0) 63 (69.2)   92 (69.2) 27 (71.1)  
 Yes 24 (30.0) 28 (30.8)   41 (30.8) 11 (28.9)  
LDHb (U/L)    0.25    0.27
 ≤ 245 55 (55.6) 44 (47.3)   81 (53.6) 18 (43.9)  
 > 245 44 (44.4) 49 (52.7)   70 (46.4) 23 (56.1)  
ALPc (U/L)    0.17    0.42
 ≤ 110 93 (92.1) 86 (86.0)   138 (87.9) 41 (93.2)  
 > 110 8 (7.9) 14 (14.0)   19 (12.1) 3 (6.8)  
β2-MGd (mg/L)    0.06    0.01
 ≤ 2.52 25 (69.4) 21 (48.8)   41 (66.1) 5 (29.4)  
 > 2.52 11 (30.6) 22 (51.2)   21 (33.9) 12 (70.6)  
Ki-67e (%)    0.74    0.75
 < 90 45 (61.6) 45 (64.3)   70 (63.6) 20 (60.6)  
 ≥ 90 28 (38.4) 25 (35.7)   40 (36.4) 13 (39.4)  
GCB subtypef    0.02    0.04
 Non-GCB 61 (61.6) 77 (77.0)   102 (65.8) 36 (81.8)  
 GCB 38 (38.4) 23 (23.0)   53 (34.2) 8 (18.2)  
Rituximabg    0.62    0.10
 No 40 (43.0) 42 (46.7)   59 (41.5) 23 (56.1)  
 Yes 53 (57.0) 48 (53.3)   83 (58.5) 18 (43.9)  
First-line chemotherapy CRh    0.61    0.15
 No 31 (33.7) 31 (36.9)   46 (32.6) 16 (45.7)  
 Yes 61 (66.3) 53 (63.1)   95 (67.4) 19 (54.3)  
First-line chemotherapy resistancei    0.36    0.03
 No 83 (90.2) 72 (85.7)   128 (90.8) 27 (77.1)  
 Yes 9 (9.8) 12 (14.3)   13 (9.2) 8 (22.9)  
Relapse    0.12    0.93
 No 89 (85.6) 77 (77.0)   130 (81.2) 36 (81.8)  
 Yes 15 (14.4) 23 (23.0)   30 (18.8) 8 (18.2)  
Death    0.09    0.34
 No 69 (66.3) 55 (55.0)   100 (62.5) 24 (54.5)  
 Yes 35 (33.7) 45 (45.0)   60 (37.5) 20 (45.5)  
  1. IPI international prognostic index, LDH lactate dehydrogenase, ALP anaplastic lymphoma kinase, β2-MG β2-microglobulin, GCB germinal center B-cell-like, CR complete remission
  2. aThe data of 33 patients were missing
  3. bThe data of 12 patients were missing
  4. cThe data of 3 patients were missing
  5. dThe data of 125 patients were missing
  6. eThe data of 61 patients were missing
  7. fThe data of 5 patients were missing
  8. gThe data of 21 patients were missing
  9. hThe data of 28 patients were missing
  10. iThe data of 28 patients were missing